Data on Solid Cancer Reported by Nicolas Andre and Colleagues (METRO-PD1: Phase 1 study of nivolumab in combination with metronomic chemotherapy in children and adolescents with relapsing/refractory solid tumors).

A Phase I study conducted in Marseille, France evaluated the combination of nivolumab, an immunotherapy drug, with three different metronomic chemotherapy regimens in children and adolescents with relapsing/refractory solid tumors. The study aimed to assess the feasibility and safety of the regimens. Sixteen patients were enrolled, and no dose-limiting toxicities were observed. Grade 3 adverse events were reported in 50% of patients, and the 6-month progression-free survival and overall survival rates were 12% and 44%, respectively. The study concluded that a randomized Phase II trial is currently underway to further evaluate the addition of nivolumab to the triple metronomic chemotherapy. [Extracted from the article]